Dyne Financial Statements From 2010 to 2026

DYN Stock  USD 18.50  1.06  5.42%   
Dyne Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Dyne Therapeutics' valuation are provided below:
Market Capitalization
B
Earnings Share
(3.62)
We have found one hundred twenty available fundamental signals for Dyne Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Dyne Therapeutics' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 4th of January 2026, Market Cap is likely to drop to about 867.2 M. In addition to that, Enterprise Value is likely to drop to about 764.3 M

Dyne Therapeutics Total Revenue

0.0

Check Dyne Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dyne Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 2.5 M or Selling General Administrative of 75.4 M, as well as many indicators such as Price To Sales Ratio of 6.54, Dividend Yield of 0.0 or PTB Ratio of 3.36. Dyne financial statements analysis is a perfect complement when working with Dyne Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Dyne Stock
Check out the analysis of Dyne Therapeutics Correlation against competitors.
To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.

Dyne Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets591 M622.1 M4.6 B
Slightly volatile
Short and Long Term Debt Total20.5 M21.6 M2.1 B
Slightly volatile
Other Current Liabilities26.4 M27.8 M159.6 M
Slightly volatile
Total Current Liabilities36.1 M38 M348.4 M
Slightly volatile
Property Plant And Equipment Net25.7 M27 M2.8 B
Slightly volatile
Current Deferred RevenueM6.3 M21.6 M
Slightly volatile
Accounts Payable5.6 M5.9 M118.3 M
Slightly volatile
Cash406.2 M391.9 M499 M
Slightly volatile
Non Current Assets Total27.3 M28.8 M3.6 B
Slightly volatile
Cash And Short Term Investments465.5 M578 M576 M
Pretty Stable
Net Receivables331.3 M590 M414.3 M
Slightly volatile
Good Will712.6 M887.8 M764.6 M
Slightly volatile
Common Stock Total Equity4.3 K4.5 K708 K
Slightly volatile
Common Stock Shares Outstanding80.5 M84.7 M143.1 M
Slightly volatile
Short Term Investments249.7 M237.8 M96.5 M
Slightly volatile
Liabilities And Stockholders Equity591 M622.1 M4.6 B
Slightly volatile
Non Current Liabilities Total16.4 M17.2 M2.2 B
Slightly volatile
Inventory267.9 M511.8 M360.5 M
Slightly volatile
Other Current Assets14.5 M15.3 M148.2 M
Slightly volatile
Total Liabilities52.5 M55.3 M3.2 B
Slightly volatile
Property Plant And Equipment Gross31.5 M33.1 M2.8 B
Slightly volatile
Total Current AssetsB593.4 MB
Slightly volatile
Short Term Debt4.1 M4.4 M32.7 M
Slightly volatile
Intangible Assets21.4 M22.5 M91.6 M
Slightly volatile
Common Stock8.6 KK709 K
Slightly volatile
Capital Surpluse7.7 M7.3 M3.1 M
Slightly volatile
Capital Stock8.6 KK1.6 M
Very volatile
Non Current Liabilities Other2.7 MM3.3 M
Slightly volatile
Net Working Capital745.1 M709.6 M185.8 M
Slightly volatile
Property Plant Equipment46.4 M44.2 M14.8 M
Slightly volatile
Other Liabilities33.6 K37.8 K41.3 K
Slightly volatile
Other Assets1.091.15408.3 K
Slightly volatile

Dyne Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.9 MM219 M
Slightly volatile
Other Operating Expenses294 M309.5 M851.8 M
Slightly volatile
Cost Of Revenue1.9 MM752.3 M
Slightly volatile
Interest Income32.5 M31 MM
Slightly volatile
Research Development339.8 M323.6 M89.1 M
Slightly volatile
Reconciled Depreciation1.1 M1.9 M608.7 K
Slightly volatile
Selling And Marketing ExpensesM2.2 M2.4 M
Slightly volatile

Dyne Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow406.7 M393.7 M499.8 M
Slightly volatile
Dividends Paid17.9 M19.8 M22 M
Slightly volatile
Issuance Of Capital Stock933.5 M889 M196.9 M
Slightly volatile
Change To Netincome21.9 M20.9 M7.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.546.8999.1591
Slightly volatile
Days Sales Outstanding316333K
Slightly volatile
EV To Sales20.1721.24153
Slightly volatile
Inventory Turnover8.497.586.9881
Pretty Stable
Days Of Inventory On Hand48.7349.8661.1572
Pretty Stable
Payables Turnover0.370.396.2331
Slightly volatile
Capex To Revenue0.480.514.1796
Slightly volatile
Cash Per Share3.936.145.5139
Very volatile
Days Payables Outstanding8269611.5 K
Slightly volatile
Intangibles To Total Assets0.03780.06090.0586
Pretty Stable
Current Ratio14.7414.048.3244
Slightly volatile
Receivables Turnover1.081.1317.2147
Slightly volatile
Capex Per Share0.02760.0290.9016
Slightly volatile
Revenue Per Share5.382.814.598
Pretty Stable
Interest Debt Per Share0.280.2917.4165
Slightly volatile
Debt To Assets0.02970.03120.2651
Slightly volatile
Graham Number9.2110.0212.4786
Slightly volatile
Operating Cycle3643834.1 K
Slightly volatile
Days Of Payables Outstanding8269611.5 K
Slightly volatile
Quick Ratio14.7414.048.145
Slightly volatile
Cash Ratio9.749.275.9132
Slightly volatile
Days Of Inventory Outstanding48.7349.8661.1572
Pretty Stable
Days Of Sales Outstanding350333246
Slightly volatile
Fixed Asset Turnover0.06220.06550.1232
Slightly volatile
Debt Ratio0.02970.03120.2651
Slightly volatile
Price Sales Ratio6.546.8999.1591
Slightly volatile
Asset Turnover0.0470.04940.0805
Slightly volatile

Dyne Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap867.2 M912.9 M1.9 B
Slightly volatile
Enterprise Value764.3 M804.5 M1.9 B
Slightly volatile

Dyne Fundamental Market Drivers

Dyne Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Dyne Therapeutics Financial Statements

Dyne Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Dyne Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue6.3 MM
Cost Of RevenueM1.9 M
Sales General And Administrative To Revenue 0.34  0.32 
Capex To Revenue 0.51  0.48 
Revenue Per Share 2.81  5.38 
Ebit Per Revenue(0.94)(0.89)

Pair Trading with Dyne Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dyne Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dyne Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Dyne Stock

  0.63GILD Gilead SciencesPairCorr

Moving against Dyne Stock

  0.54HD Home DepotPairCorr
  0.52MGMA Metro Global MediaPairCorr
  0.32PG Procter GamblePairCorr
  0.31HPQ HP IncPairCorr
The ability to find closely correlated positions to Dyne Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dyne Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dyne Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dyne Therapeutics to buy it.
The correlation of Dyne Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dyne Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dyne Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dyne Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Dyne Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dyne Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dyne Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dyne Therapeutics Stock:
Check out the analysis of Dyne Therapeutics Correlation against competitors.
To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.62)
Return On Assets
(0.34)
Return On Equity
(0.61)
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.